Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript

Page 4 of 4

Operator: Thank you. That concludes today’s question-and-answer session. I will now turn the call over to the management team for any closing remarks.

Daniel O’Day: Great. This is Dan. I just want to do a couple of things here. First of all, thank you all for joining and your on-going interest and questions for Gilead. As usual, if we didn’t get to all of your questions, please reach out to Investor Relations. As you know, we’re very happy to answer those on an on-going basis. Now let me just close by emphasizing that Gilead is in a very different place than it was a few years ago, thanks to the work the team has done to transform the company. We’re going into 2023 in a very strong position with our current medicines performing well and tremendous growth potential in our neuro therapies as well as those in development. So what you can expect to see next is quarter-on-quarter execution and even faster progress and greater impact in the future. Thank you very much for your time today, and we look forward to speaking to you again soon.

Operator: That concludes today’s fourth quarter and full year 2022 Gilead Sciences earnings conference call. Thank you for your participation.

Follow Gilead Sciences Inc. (NASDAQ:GILD)

Page 4 of 4